Gain Therapeutics updates on GT-02287 Phase 1b trial for Parkinson's disease

Gain Therapeutics, Inc.

Phase 1b trial of GT-02287 approved; dosing imminent in Australia, enrolling 15-20 patients with GBA1 or idiopathic PD.
Prior healthy volunteer study showed 53% increase in GCase activity and confirmed safety/tolerability.
Cash of $12M as of September 30, 2024, expected to fund operations through interim analysis in 2Q 2025.
FDA pre-IND meeting found no significant regulatory hurdles; IND submission on track for Phase 2 planning in 2H 2025.
Promotion of Gianluca Fuggetta to SVP Finance; company exploring licensing partners and financing options.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.